CTI's pixantrone trial data confirmed by second radiology panel

Cell Therapeutics (CTI) today announced that a second independent radiology assessment of the data from the biotech's PIX301 clinical trial (also known as the EXTEND trial) of pixantrone for relapsed or refractory non-Hodgkin's lymphoma "confirmed the statistical robustness" of the data previously submitted to the FDA.

CTI followed through with this second independent radiology assessment—in which a panel of three radiologists examine the data without knowing which arm the patient was in—because it had been part of the recommendations made by the FDA's Office of New Drugs, an aspect of the biotech's appeal of the Complete Response Letter they received from the FDA's Office of Oncology Drug Products last year.

According to James A. Bianco, M.D., CEO of CTI, "The review conducted by a second independent panel of three radiologists confirmed the statistically and clinically significant results the first independent panel reported for the PIX301 study response and progression endpoints."

Curiously, this is the same "statistically robust" data that an independent panel unanimously found insufficient enough to reject in the spring of 2010.

In addition to their ongoing appeal, CTI should be busy recruiting 350 patients for its PIX-R trial.

Further Reading

CTI News Release
Shareholders file class action lawsuit against CTI
CTI: Putting the BO in Biotech

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap